You are here
Regulated information
|
September 02, 2021
bioMérieux - 2021 HY Financial Results
|
|
September 02, 2021
2021 HY Financial Report
|
|
September 02, 2021
Notice of Publication of the 2021 HY Financial Report
|
|
September 02, 2020
Notice of Publication of the 2020 HY Financial Report
|
|
September 02, 2020
Interim Financial Report 2020
|
|
July 27, 2015
These information have been shifted to the Registration Document, now called Universal Registration Document
|
|
May 13, 2014
bioMérieux Rapport du Président 2013
|
|
April 22, 2013
Report of the Chairman of the Board of Directors on Corporate Governance and Internal control report
|
|
April 22, 2013
Avis de mise à disposition du Rapport du Président du Conseil d'administration sur le contrôle interne
|
|
April 30, 2010
Rapport sur le gouvernement d'entreprise et le contrôle interne 2009
|
|
July 27, 2015
These information have been shifted to the Registration Document, now called Universal Registration Document
|
|
May 13, 2014
bioMérieux Honoraires des commissaires aux comptes 2013
|
|
April 15, 2013
Honoraires des Commissaires aux Comptes 2012
|
|
April 28, 2010
Honoraires des Commissaires aux Comptes 2009 et 2008
|
|
June 11, 2009
Prospectus 2008
|
|
September 06, 2021
August 2021 - Declaration about number of shares issued and number of voting rights
|
|
August 12, 2021
July 2021 - Declaration about number of shares issued and number of voting rights
|
|
July 07, 2021
June 2021 - Declaration about number of shares issued and number of voting rights
|
|
June 10, 2021
May 2021 - Declaration about number of shares issued and number of voting rights
|
|
May 05, 2021
April 2021 - Declaration about number of shares issued and number of voting rights
|
|
October 10, 2013
Communiqué de mise à disposition du Prospectus Emission Obligataire visé par l'AMF Octobre 2013
|
|
May 07, 2004
Document de Base
|
|
September 13, 2021
A survey in 5 European countries about sepsis demonstrates the lack of awareness and an expectation for faster diagnostic capabilities
|
|
September 01, 2021
bioMérieux – First-Half 2021 Results
|
|
June 29, 2021
In the fight against Antimicrobial Resistance, bioMérieux and Specific Diagnostics announce a co-exclusive distribution agreement for the SPECIFIC REVEAL® Rapid AST system in Europe
|
|
June 24, 2021
bioMérieux launches EPISEQ® SARS-COV-2, a cloud-based software application for the epidemiological surveillance of SARS-CoV-2 variants
|
|
May 10, 2021
bioMérieux announces the CE marking of the new generation semi-quantitative VIDAS® SARS-COV-2 IgG II serology test.
|
|
April 09, 2021
Notice of information related to preparatory documents for the Ordinary and Extraordinary Shareholders’ Meeting of May 20, 2021
|
|
May 22, 2020
Notice of information related to preparatory documents for the Ordinary and Extraordinary Shareholders’ Meeting of June 30, 2020
|
|
July 07, 2021
Biannual report on bioMérieux's liquidity agreement as of June 30, 2021
|
|
May 20, 2021
AG 2021 - Description of share repurchase program
|
|
March 15, 2021
Disclosure of trading in own shares on March15, 2021
|
|
March 08, 2021
Disclosure of trading in own shares on March 8, 2021
|
|
January 22, 2021
Biannual report on bioMérieux's liquidity agreement as of december 31, 2020
|
No regulated information available